#RNAtherapy

[healtharkinsightss]

Fitusiran: A Breakthrough in Hemophilia Care

With just six injections a year, Fitusiran is set to transform hemophilia treatment by leveraging cutting-edge RNA therapy. This innovation offers a new hope for patients with Hemophilia A and B, addressing long-term challenges with precision and efficiency

[fromsciencetopharma]

MSL DAILY RESEARCH NEWS - AZ, Accent to develop therapies targeting RNA-modifying proteins #Astrazeneca #RNAtherapy “The collaboration focuses on targeting RMPs, proteins that control various aspects of RNA biology which represent a new approach for addressing the process disruptions that can lead to cancer and treatment resistance. According to the firms, the move will bring together AZ’ expertise in progressing novel oncology medicines and Accent’s expertise in the biology, target identification and drug discovery of RMP-targeting therapies. Under the terms of the deal, Accent takes responsibility for research and development activities for a nominated preclinical programme through to the end of Phase I clinical trials.” Free webinar on “how to become an MSL” https://lnkd.in/gFYBJ2G Or click on our profile. Click below to read further, like and share it and follow us to learn more. Our MSL testimonials: Http://https://lnkd.in/eEfHu4c #MSL #FSTP #MSLcert #medicalscienceliaison https://www.instagram.com/p/CBMEUlzDEKg/?igshid=l77w3izztkcv

[lifeuniverseverythingscienc-blog]

RNA THERAPY FOR PSORIASIS

Image:  International Institute for Nanotechnology at Northwestern University

A phase 1 trial conducted by a private startup called Exicure has shown that the treatment could be used to fight psoriasis. Psoriasis is an auto-immune disease, triggered when the body creates too much of a normally healthy protein, tumor necrosis factor-α (TNF-α). The immune system attacks this protein, causing red, itchy, and scaly skin patches.

RNA acts as a messenger between your DNA and protein. One of the ways scientists have been able to limit protein creation, such as the overproduction of TNF- α, is by destroying RNA genes using a relatively new technique called spherical nucleic acid (SNA), a form of RNA interference, or RNAi.

Exicure has shown in the past that SNAs can lower the amount of TNF-α in animal trials. Now, the initial trial results of the clinical trial suggest that SNAs are safe and that there appears to be a dose-dependent response in knocking down TNF-α, which suggests that doctors will be able to find a curative dose. This means that although there is more work to do in finding the correct dose, a treatment could be on the way for those suffering psoriasis.

If the treatment continues to show promise in this and other follow-up trials, it’s just the beginning for similar SNA therapies, with the potential for more new drugs based on this technique to target cancer-causing genes, and a number of auto-immune diseases.

The results are not yet published.

Follow us on … Tumblr: http://tinyurl.com/nozt3gl Facebook: http://tinyurl.com/mbg2ldh